Pfizer Inc. (PFE)
| Market Cap | 149.05B |
| Revenue (ttm) | 63.83B |
| Net Income (ttm) | 10.75B |
| Shares Out | 5.69B |
| EPS (ttm) | 1.89 |
| PE Ratio | 13.84 |
| Forward PE | 9.39 |
| Dividend | $1.72 (6.56%) |
| Ex-Dividend Date | Jul 25, 2025 |
| Volume | 37,017,549 |
| Open | 26.42 |
| Previous Close | 26.43 |
| Day's Range | 26.05 - 26.58 |
| 52-Week Range | 20.92 - 30.43 |
| Beta | 0.47 |
| Analysts | Hold |
| Price Target | 29.55 (+12.72%) |
| Earnings Date | Nov 4, 2025 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for PFE stock is "Hold." The 12-month stock price target is $29.55, which is an increase of 12.72% from the latest price.
News
Pfizer Offers High Yield And Capital Appreciation Opportunities (Technical Analysis)
Pfizer surged 15% last week on positive news, including a direct-to-consumer deal and a three-year tariff reprieve. PFE offers a high 6.28% yield, with a forward PE of 8.87, and its dividend is consid...
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
Pfizer: TrumpRx Unlocks Opportunities With Drug Discounts
Pfizer delivered strong 2Q25 results with double-digit revenue growth, margin expansion, and robust earnings driven by Comirnaty, Paxlovid, and Vyndaqel. The TrumpRx deal offers discounted direct-to-c...
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (Oct. 2025)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filter...
The Score: Pfizer, Tesla, Electronic Arts and More Stocks That Defined the Week
Here are some of the major companies whose stocks moved on the week's news
Pharmaceutical Stocks: Valuations And Pipelines Are Only Beginning To Be Appreciated
Drug stocks are poised to outperform in 2025, driven by conservative valuations and a research renaissance in key therapeutic areas. US healthcare spending growth and transformative GLP-1 therapies, e...
The drug price deal between Pfizer and the Trump administration was built on down-to-the-wire team negotiations, building on a relationship between CEO Albert Bourla and President Trump
Down-to-the wire team negotiations capped a long dance between President Trump and CEO Albert Bourla.
Pfizer: The Long Suffering Is Finally Over (Rating Upgrade)
Pfizer Inc. has secured an MFN pricing deal with the White House, easing recent tariff and drug repricing concerns while affording a win for Trump. PFE's solid dividend yield of >6% provides a robust ...
Heard on the Street: Pfizer's accord on price cuts with President Trump clears a cloud over the whole pharma industry
The company's accord with the president clears a cloud over the whole sector.
Why Pfizer's Trump Deal Is Good News for All of Big Pharma
The company's accord with the president clears a cloud over the whole sector.
Final Trade: GDX, PFE, GFS, BMY
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
‘Fast Money' traders talk opportunities in health care stocks
The Fast Money traders discuss why health care stocks look attractive on valuations, how underweight positioning could drive sustainability, why recent White House policy moves may be a “gift” to phar...
Pfizer's Art Of The Deal
President Trump and Pfizer announced a deal to cut drug pricing yeseterday. And it looks like the pharmaceutical giant got the better end of it.
Stock Of The Day: Will Pfizer Head Higher?
Shares of Pfizer Inc. (NYSE:PFE) continue to head higher on Wednesday, a day after the company announced that it has secured a three-year grace period from President Donald Trump's tariffs on pharmace...
Pfizer's TrumpRx Pact Sends Shockwaves: Why UnitedHealth, Lilly And CVS Can't Look Away
Pfizer Inc's (NYSE:PFE) deal with Washington isn't just a handshake in the Oval Office — it's a seismic jolt to America's drug-pricing game. By agreeing to sell medicines on the government's new Trump...
Pfizer Drug-Pricing Deal: More Upside For PFE Stock?
Pfizer stock (NYSE: PFE) offers a compelling investment opportunity at its current price of around $25, supported by attractive valuations and recent policy changes that may present further upside pot...
Trump's pharmaceutical tariff threat loses bite after Pfizer deal reassures drugmakers
President Donald Trump's long-awaited threat to impose pharmaceutical tariffs may not pose as much of a challenge as drugmakers once feared, following his new drug-pricing deal with Pfizer. Trump's ag...
Pres. Trump's deal with Pfizer is pretty devastating to PBMs and insurance companies: John Lamattina
John Lamattina, PureTech Health senior partner and former Pfizer Global R&D president, joins 'Squawk Box' to discuss President Trump's deal with Pfizer, impact on drug prices, what the deal means for ...
Swiss pharma companies likely to follow Pfizer-U.S. price deal, says business lobby
Swiss pharma companies are likely to follow Pfizer's price deal with the U.S. following a demand from President Donald Trump's administration for lower drug prices, the head of a major Swiss chemical ...
European healthcare stocks surge as U.S. Pfizer deal reduces some uncertainty
European healthcare stocks jumped on Wednesday, a day after Pfizer and U.S. President Donald Trump said the U.S.-based drugmaker agreed to lower prescription drug prices in the Medicaid program in exc...
Astellas To Present Pioneering Advances Across Its Portfolio and Pipeline at ESMO 2025
- New clinical data across ten accepted abstracts demonstrate significant progress across Astellas' innovative oncology programs - - Results from the EV-303 trial (also known as KEYNOTE-905) in cispla...
Explainer: What does Trump's deal with Pfizer mean for drug prices?
President Donald Trump, who has long argued that the U.S. pays more than it should for prescription medicines, on Tuesday said Pfizer had agreed to cut prices for drugs it sells to the Medicaid progra...
Pfizer strikes deal with the White House to lower drug prices
The Trump administration announced a deal with pharmaceutical giant Pfizer (PFE) to lower drug prices while gaining an exemption from the president's tariff policies. Watch President Trump's remarks h...
S&P 500 Gains and Losses Today: Pfizer and Merck Jump; Payments Stocks Decline
An agreement with the U.S. government and a favorable regulatory decision in Europe helped lift shares of large drugmakers. Meanwhile, the announcement of a collaboration that will integrate shopping ...
Shutdown deadline ticks closer with no deal in sight, Pfizer & Trump ink deal to lower drug prices
Market Domination host Josh Lipton breaks down the biggest market stories ahead of the closing bell on September 30, 2025. US lawmakers have failed to compromise on a deal and avert a government shutd...